Strategic Positioning and Market Presence
Despite a net loss, Pacific Edge maintains a strong strategic position by achieving significant milestones and maintaining a U.S. market presence to appeal Medicare and commercial tests. The company is in the strongest position to drive Medicare policy change.
Contractor Advisory Committee and Evidence Portfolio
Novitas has convened a Contractor Advisory Committee (CAC) for February 2026, acknowledging the evidence behind urine-based biomarkers for hematuria evaluation, largely driven by Cxbladder's evidence portfolio.
Triage Plus Economic Uplift
Achieved a critical milestone with Triage Plus locked in at $1,328 per test, a significant increase from the previous $760 per test.
APAC Revenue Growth
APAC contributed 15% of revenue for the half, up from 8% in the second half of FY '25.